GLPBio

Immunology/Inflammation

Read More about this category

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Research Areas

Products Related to Immunology/Inflammation(4746)

  • GC74270 structure
    GC74270Penduletin
    CAS: 569-80-2
    Purity: >99.00%

    Penduletin هو فلافون، الذي يمكن عزله من Brickelia pendula و Vitex negundo.

  • GC74298 structure
    GC74298Oxidized low density lipoprotein (Human)

    Oxidized low density lipoprotein (Human) الإنسان ox-LDL تشارك في التصلب.

  • GC74304 structure
    GC74304PSMA targeting peptide TFA
    Purity: >99.00%

    PSMA targeting peptide TFA (PSMA-1 TFA) هو ببتيد استهداف PSMA (GRFLTGGTGRLLRIS) ويمكن استخدامه للتوصيل المستهدف للبروتين المنظمة للجلوكوز (GRP)-إسكات siRNAs في خلايا PCA.

  • GC74307 structure
    GC743073BP-3940
    CAS: 2803421-14-7
    Purity: >99.00%

    3BP-3940 هو ببتيد لتنشيط الأرومات الليفية القوية للغاية (FAP) يستهدف الثيرانوستيك.

  • GC74313 structure
    GC74313MYBMIM
    Purity: >99.00%

    MYBMIM هو مثبط لتجميع جزيئي MYB: CBP/P300.

  • GC74317 structure
    GC74317S7
    CAS: 853248-13-2
    Purity: >99.00%

    S7 هو مضاد مستقبلات IL-6 ويمنع الارتباط بين IL-6 و IL-6R.

  • GC74335 structure
    GC74335Icotrokinra
    CAS: 2763602-16-8
    Purity: >99.00%

    Icotrokinra (JNJ-77242113) هو مضاد انتقائي متاح عن طريق الفم لمستقبلات IL-23.

  • GC74339 structure
    GC74339Ac2-26 ammonium
    Purity: >98.00%

    Ac2-26 ammonium هو ببتيد N-terminal من الضم 1، وله نشاط مضاد للالتهابات.

  • GC74354 structure
    GC74354Pegcetacoplan acetate
    Purity: >98.00%

    Pegcetacoplan acetate هو ببتيد مثبط C3 مكمل.

  • GC74402 structure
    GC74402HYNIC-iPSMA TFA
    CAS: 2375849-11-7
    Purity: >99.00%

    HYNIC-iPSMA TFA هو ربيطة للتصوير الجزيئي للأورام. يتكون إيسما nic-ipsma من مكونين: NIC (6-drazinonicotinamide) و iPSMA (مانع مستضد الغشاء الخاص بالبروستاتا).

  • GC74423 structure
    GC74423Vamikibart
    CAS: 2744320-12-3
    Purity: >99.00%

    Vamikibart هو كائن مضاد IgG2κ المبشر يستهدف IL6.

  • GC74425 structure
    GC74425Casdozokitug
    CAS: 2643331-37-5
    Purity: >96.00%

    Casdozokitug (SRF-388) هو جسم مضاد من نوع IgG1κ يستهدف IL27.

  • GC74439 structure
    GC74439Picankibart
    CAS: 2622900-74-5
    Purity: >98.00%

    Picankibart هو جسم مضاد مستمد من الفأر IgG1κ يستهدف IL23A.

  • GC74446 structure
    GC74446Rademikibart
    CAS: 2648260-80-2
    Purity: >98.00%

    Rademikibart (CBP-201) هو جسم مضاد بشري وحيد النسيلة يستهدف IL-4Rα مع KD 20.7 pM عندما يرتبط بحواتم IL-4Rα البشرية.

  • GC74451 structure
    GC74451Enfortumab vedotin-ejfv (solution)
    CAS: 1346452-25-2
    Purity: >99.00%

    Enfortumab vedotin-ejfv (solution) هو مضاد للأجسام المضادة Nectin-4 الدواء المقترن لإدارة سرطان الغدة البولية.

  • GC74457 structure
    GC74457Lunsekimig
    Purity: >98.00%

    Lunsekimig هو جسم مضاد أحادي النسل مضاد لـ TSLP/IL13/ALB يتكون من 5 سلاسل ثقيلة ذات منطقة متغيرة مرتبطة بالتسلسل.

  • GC74471 structure
    GC74471Camidanlumab
    CAS: 921618-45-3
    Purity: >99.00%

    Camidanlumab (HuMax-TAC) هو جسم مضاد وحيد النسل من نوع CD25.

  • GC74476 structure
    GC74476Seribantumab
    CAS: 1334296-12-6
    Purity: >95.00%

    Seribantumab (MM 121) هو جسم مضاد وحيد النسيلة من النوع IgG2 يستهدف هيرب 3.

  • GC74477 structure
    GC74477Tigatuzumab
    CAS: 918127-53-4
    Purity: >95.00%

    Tigatuzumab (CS-1008) هو جسم مضاد وحيد النسل IgG1 إنساني يستهدف مستقبلات الموت 5 (DR5).

  • GC74482 structure
    GC74482Drozitumab
    CAS: 912628-39-8
    Purity: >99.00%

    Drozitumab (PRO 95780) هو جسم مضاد بشري مضاد وحيد النسيلة يربط مستقبلات الموت DR5.

  • GC74483 structure
    GC74483Galiximab
    CAS: 357613-77-5
    Purity: >99.00%

    Galiximab (IDEC 114) هو جسم مضاد أولي من الغلوبولين المناعي G1 lambda أحادي النسل موجه ضد مستضد CD80 ويمنع ارتباط CD80-CD28.

  • GC74486 structure
    GC74486Lexatumumab
    CAS: 845816-02-6
    Purity: >96.00%

    Lexatumumab (HGS-ETR 2) هو كائن بشري ناهض مستقبلات TRAIL 2 (TRAIL-R2, DR5, APO-2) الجسم المضاد أحادي النسيلة IgG4κ من النوع.

  • GC74488 structure
    GC74488Sirukumab
    CAS: 1194585-53-9
    Purity: >95.00%

    Sirukumab (بالإنجليزية: Sirukumab (CNTO-136)) هو جسم مضاد وحيد النسيلة لـ IL6 (مرتبط بالإنترلوكين) من نوع IgG1k.

  • GC74490 structure
    GC74490Tositumomab
    CAS: 192391-48-3

    Tositumomab هو جسم مضاد وحيد النسل من نوع الفئران IgG2a lambda موجه ضد مستضد CD20، والذي يوجد على سطح الخلايا الليمفاوية B الطبيعية والخبيثة.